Cyclophosphamide for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Anemia, Refractory, with Excess of Blasts

Why this status

  1. 13 Dec 2012: Trial registered, NCT01749111

The trials

NCT01749111: Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis

State
Stopped early
Phase
Phase 3
People
3 taking part
Started
Dec 2012
Primary completion
Aug 2016
Arms
Arm A
Results
None posted
  1. 13 Dec 2012: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as ARM A Cyclophosphamide, Cycloblastin, Cyclostin, Cytophosphan, Cytoxan, Cyclophosphamide 250 mg/m2; 3 days, Cyclophosphamide 35mg/kg/day, Cyclophosphamide 500 mg/m2; 2 doses, Cyclophosphamide 500 mg/m2; 3 doses, Cyclophosphamide 900 mg/m2; 1 day, Endoxan, Neosar, Procytox, Revimmune.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.